Skip to main content
. 2013 Feb 25;8(2):e57053. doi: 10.1371/journal.pone.0057053

Figure 1. The IL4 pathway was enriched in both tumor progression and chemotherapy signatures.

Figure 1

Eleven out of the 49 IL4 pathway-involved genes were mapped in the pathway enrichment analysis for the 3,858 differentially expressed transcripts in PBMC among patients with advanced non-small ell lung cancer (NSCLC) and normal controls, whereas 16 unique genes were mapped for the 669 differentially expressed transcripts in PBMC of patients with advanced-stage NSCLC before and after chemotherapy. Seven intersected genes between the two gene-sets were identified and presented in a Venn diagram. The blue circle indicates differentially expressed genes associated with tumor progression solely, the red circle with chemotherapy solely, and the purple circle with both effects.